Stock listing
NASDAQ:AARD Aardvark Therapeutics, Inc. Stock
Home listing (NASDAQ) of Aardvark Therapeutics, Inc.
Follow Aardvark Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AARD
$0.923 USD -0.077 (-7.7%)
Close on Nov 20, 2026
- Day range
- $0.900 – $1.060 USDNov 20, 2026
- Volume
- 241,067 sharesNov 20, 2026
- Market cap
- $20.20M USDAt the close on Nov 20, 2026 · price × 21.89M shares outstanding
- 52-week range
- $0.900 – $16.600 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.23M USDMedian day 191,550 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AARD · Home | $0.923 USD | -0.077 (-7.7%) | 241,067 | $1.000 | $1.060 | $0.900 | $1.000 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AARD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.923 | -0.077 | -7.7% | $1.000 | $1.060 | $0.900 | 241,067 | |
| $1.000 | +0.090 | +9.9% | $0.960 | $1.100 | $0.950 | 486,486 | |
| $0.910 | -0.240 | -20.9% | $1.160 | $1.210 | $0.906 | 530,041 | |
| $1.150 | -0.110 | -8.7% | $1.240 | $1.380 | $1.100 | 475,501 | |
| $1.260 | -0.070 | -5.3% | $1.330 | $1.480 | $1.210 | 215,221 | |
| $1.330 | -0.190 | -12.5% | $1.580 | $1.700 | $1.310 | 402,400 | |
| $1.520 | -0.070 | -4.4% | $1.580 | $1.615 | $1.510 | 249,800 | |
| $1.590 | +0.220 | +16.1% | $1.350 | $1.680 | $1.340 | 387,500 | |
| $1.370 | +0.020 | +1.5% | $1.320 | $1.440 | $1.290 | 242,600 | |
| $1.350 | +0.180 | +15.4% | $1.210 | $1.420 | $1.171 | 682,800 | |
| $1.170 | +0.060 | +5.4% | $1.100 | $1.180 | $1.090 | 221,700 | |
| $1.110 | -0.150 | -11.9% | $1.180 | $1.231 | $1.095 | 374,600 | |
| $1.260 | +0.030 | +2.4% | $1.250 | $1.280 | $1.169 | 216,200 | |
| $1.230 | +0.030 | +2.5% | $1.220 | $1.290 | $1.210 | 263,400 | |
| $1.200 | -0.160 | -11.8% | $1.370 | $1.396 | $1.200 | 339,200 | |
| $1.360 | -0.080 | -5.6% | $1.390 | $1.460 | $1.330 | 463,800 | |
| $1.440 | -0.070 | -4.6% | $1.480 | $1.530 | $1.362 | 955,900 | |
| $1.510 | +0.210 | +16.2% | $1.220 | $1.590 | $1.176 | 2,019,000 | |
| $1.300 | +0.220 | +20.4% | $1.090 | $1.390 | $1.090 | 4,282,800 | |
| $1.080 | -0.310 | -22.3% | $1.245 | $1.390 | $0.930 | 4,957,700 | |
| $1.390 | -2.560 | -64.8% | $2.990 | $3.000 | $1.390 | 16,346,500 | |
| $3.950 | -0.460 | -10.4% | $4.270 | $4.310 | $3.890 | 1,415,300 | |
| $4.410 | +0.510 | +13.1% | $3.950 | $4.540 | $3.950 | 218,400 | |
| $3.900 | +0.160 | +4.3% | $3.800 | $4.051 | $3.780 | 66,700 | |
| $3.740 | -0.040 | -1.1% | $3.750 | $4.050 | $3.640 | 129,800 | |
| $3.780 | -0.080 | -2.1% | $4.190 | $4.190 | $3.730 | 97,200 | |
| $3.860 | -0.020 | -0.5% | $3.860 | $3.977 | $3.770 | 68,800 | |
| $3.880 | -0.160 | -4.0% | $3.930 | $4.350 | $3.830 | 126,100 | |
| $4.040 | -0.410 | -9.2% | $4.440 | $4.630 | $4.030 | 218,300 | |
| $4.450 | -0.310 | -6.5% | $4.810 | $4.877 | $4.400 | 99,900 | |
| $4.760 | +0.050 | +1.1% | $4.610 | $4.820 | $4.600 | 140,900 | |
| $4.710 | -0.250 | -5.0% | $4.770 | $5.090 | $4.570 | 316,000 | |
| $4.960 | -0.080 | -1.6% | $4.950 | $5.330 | $4.690 | 212,000 | |
| $5.040 | -0.180 | -3.4% | $5.280 | $5.450 | $4.660 | 251,900 | |
| $5.220 | +0.230 | +4.6% | $5.030 | $5.370 | $5.030 | 61,300 | |
| $4.990 | -0.280 | -5.3% | $5.370 | $5.660 | $4.880 | 147,700 | |
| $5.270 | 0.000 | 0.0% | $5.290 | $5.420 | $5.130 | 47,800 | |
| $5.270 | -0.080 | -1.5% | $5.420 | $5.524 | $5.270 | 28,100 | |
| $5.350 | +0.080 | +1.5% | $5.210 | $5.390 | $5.002 | 39,600 | |
| $5.270 | +0.210 | +4.2% | $5.050 | $5.320 | $4.960 | 60,600 | |
| $5.060 | -0.490 | -8.8% | $5.570 | $5.600 | $5.020 | 71,500 | |
| $5.550 | -0.010 | -0.2% | $5.550 | $5.690 | $5.325 | 96,100 | |
| $5.560 | -0.190 | -3.3% | $5.740 | $5.740 | $5.415 | 54,800 | |
| $5.750 | +0.180 | +3.2% | $5.510 | $5.840 | $5.500 | 101,300 | |
| $5.570 | +0.190 | +3.5% | $5.440 | $5.575 | $5.340 | 110,300 | |
| $5.380 | -0.150 | -2.7% | $5.440 | $5.590 | $5.190 | 129,800 | |
| $5.530 | +0.380 | +7.4% | $5.320 | $5.770 | $5.190 | 258,100 | |
| $5.150 | +0.130 | +2.6% | $5.040 | $5.290 | $4.930 | 47,900 | |
| $5.020 | -0.530 | -9.5% | $5.470 | $5.545 | $5.010 | 64,200 | |
| $5.550 | +0.420 | +8.2% | $4.900 | $5.880 | $4.800 | 216,900 | |
| $5.130 | +0.120 | +2.4% | $5.110 | $5.540 | $4.975 | 276,600 | |
| $5.010 | +0.090 | +1.8% | $4.870 | $5.015 | $4.540 | 209,400 | |
| $4.920 | -0.410 | -7.7% | $5.330 | $5.456 | $4.895 | 109,700 | |
| $5.330 | -0.050 | -0.9% | $5.330 | $5.710 | $5.100 | 164,700 | |
| $5.380 | -0.350 | -6.1% | $5.720 | $5.991 | $5.150 | 257,800 | |
| $5.730 | -0.220 | -3.7% | $5.920 | $6.190 | $5.600 | 89,300 | |
| $5.950 | +0.030 | +0.5% | $6.050 | $6.225 | $5.795 | 59,400 | |
| $5.920 | -0.180 | -3.0% | $6.000 | $6.245 | $5.807 | 85,000 | |
| $6.100 | +0.310 | +5.4% | $5.700 | $6.155 | $5.300 | 125,400 | |
| $5.790 | -0.830 | -12.5% | $6.470 | $6.470 | $5.620 | 143,000 | |
| $6.620 | -0.190 | -2.8% | $6.890 | $7.085 | $6.585 | 74,200 | |
| $6.810 | -0.440 | -6.1% | $7.290 | $7.300 | $6.210 | 111,900 | |
| $7.250 | +0.370 | +5.4% | $6.940 | $7.310 | $6.490 | 145,204 | |
| $6.880 | +0.060 | +0.9% | $6.750 | $6.970 | $6.283 | 83,299 | |
| $6.820 | +0.930 | +15.8% | $5.910 | $6.900 | $5.800 | 173,700 | |
| $5.890 | -0.860 | -12.7% | $6.760 | $7.120 | $5.760 | 250,200 |
- Ticker
- NASDAQ:AARD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · Oct 23, 2026
Technical Presentation (October 2026)
Technical · 26 slides
Latest news
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 13, 2026
Closed $1.33 (-12.5%) on Nov 13, 2026
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
Oct 23, 2026
Closed $1.39 (-64.8%) on Oct 23, 2026
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Oct 22, 2026
Closed $1.39 (-64.8%) on Oct 23, 2026
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Oct 8, 2026
Closed $4.71 (-5.0%) on Oct 8, 2026
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026
Closed $5.22 (+4.6%) on Oct 5, 2026
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 11, 2026
Closed $6.57 (-8.6%) on Aug 12, 2026
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
Closed $4.57 (-32.1%) on May 15, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Closed $5.60 (-4.9%) on May 7, 2026
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Mar 23, 2026
Closed $4.07 (-0.1%) on Mar 23, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
Feb 27, 2026
Closed $5.47 (-56.2%) on Mar 2, 2026
Aardvark Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 33 in all · newest Nov 13, 2026 · oldest 2025
- Decks
- 4 decks · latest Oct 23, 2026
Where Aardvark Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AARD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AARD | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 2.0×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$39.58M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 3.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. · NASDAQ:AARD | US$20.20M | −US$39.58M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 3.28 |
| NanoGroup SA · GPW:NNG | US$21.31M | US$18.78M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Cel-Sci Corporation · AMEX:CVM | US$21.28M | US$14.76M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.13 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.66M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.86M | US$23.45M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Vivoryon Therapeutics N.V. · EURONEXT:VVY | US$20.48M | US$17.77M | n/a | n/a | n/a | 11.9× | n/a | 0.1× | n/a |
| Evaxion A/S · NASDAQ:EVAX | US$20.30M | US$13.40M | n/a | 1.8× | n/a | 2.1× | −115.1% | 0.8× | 0.78 |
| GenSight Biologics SA · EURONEXT:SIGHT | US$20.19M | US$32.44M | n/a | 29,573× | n/a | n/a | n/a | n/a | n/a |
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Median of the others | US$20.39M | US$18.27M | 50.1× | 2.0× | −82.1% | 0.0× | 1.06 |
Forecasts
4 strong buy · 5 hold · 1 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.57 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.21 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tien Lee | Chief Executive Officer |
| Nelson Sun | Chief Operating Officer & Chief Financial Officer |
| Christopher J. Kemmerer | EVP, Technical Operations |
| Dvorit Samid | EVP, Medical Affairs |
| Justin Stege | VP, Head of Project Management and Strategy |
| Ron Lewis | VP, Head of CMC |
| David Zhang | Chief Strategy Officer |
| Derrick Li | Chief Business Officer |
| Manasi Jaiman | Chief Medical Officer |
| Victor Tong | Managing Director |
| Zhenhuan Zheng | Chief Research Officer |
Board
| Director | Role |
|---|---|
| Jeffrey Chi | Vice Chairman |
| Roy Baynes | |
| Susan E. Graf | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −12.5% |
| Q2 2026 | Aug 11, 2026 · After close | −8.6% |
| Q1 2026 | Apr 6, 2026 | −6.0% |
| Q4 2025 | Mar 23, 2026 · After close | −7.3% |
| Q3 2025 | Nov 13, 2025 · After close | −8.7% |
| Q2 2025 | Aug 13, 2025 · After close | +0.5% |
| Q1 2025 | May 14, 2025 · After close | +4.0% |
| Q4 2024 | Mar 31, 2025 | +7.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 26 slides | Oct 23, 2026 |
| Investor Presentation (January 2026) | Investor deck | 29 slides | Jan 12, 2026 |
| ObesityWeek Investor Webinar 2025 | Conference | 65 slides | Nov 6, 2025 |
| Investor Presentation (September 2025) | Investor deck | 22 slides | Sep 3, 2025 |
IPO
Priced at US$16.00 a share on Feb 12, 2025.
- Price
- US$16.00 a share
- Shares offered
- 5,888,000 shares of common stock
- Offering size
- US$94.2 million
- Underwriters' option
- Up to 883,200 more shares
- Underwriters
- MORGAN STANLEY, BofA SECURITIES, CANTOR, RBC CAPITAL MARKETS · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 24, 2024 |
| Filed publicly | Jan 23, 2025 |
| Amended once | Feb 6, 2025 |
| Shares registered with an exchange | Feb 10, 2025 |
| Declared effective by the SEC | Feb 12, 2025 |
| Final prospectus, with the price | Feb 13, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 13, 2025 |
| EFFECT · Notice that a registration is effective | Feb 12, 2025 |
| CERT · Exchange's certificate of listing | Feb 12, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 10, 2025 |
| CORRESP · Letter to the SEC | Feb 10, 2025 |
| CORRESP · Letter to the SEC | Feb 10, 2025 |
| S-1/A · Registration statement, amended | Feb 6, 2025 |
| CORRESP · Letter to the SEC | Jan 31, 2025 |
| S-1 · Registration statement | Jan 23, 2025 |
| DRS/A · Draft registration statement, amended | Dec 23, 2024 |
All 16 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Dec 20, 2024 |
| UPLOAD · Letter from the SEC | Dec 10, 2024 |
| DRSLTR · Letter to the SEC with a draft | Nov 27, 2024 |
| DRS/A · Draft registration statement, amended | Nov 27, 2024 |
| UPLOAD · Letter from the SEC | Nov 21, 2024 |
| DRS · Draft registration statement | Oct 24, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of revenue | 36.0K | 16.0K | 97.0K | 110.0K |
| Gross profit | -36.0K | -16.0K | -97.0K | -110.0K |
| Research and development | 48.9M | 17.4M | 4.48M | 7.17M |
| Selling, general and administrative | 13.8M | 5.30M | 2.17M | 2.70M |
| Operating income | -62.7M | -22.8M | -7.42M | -11.4M |
| Depreciation and amortization | 36.0K | 16.0K | 97.0K | 110.0K |
| EBITDA | -62.7M | -22.8M | -7.32M | -11.3M |
| Income before tax | -57.6M | -20.6M | -7.21M | -13.6M |
| Income tax | 0 | 0 | ||
| Net income | -57.6M | -20.6M | -7.21M | -13.6M |
| Earnings per share, basic | -2.93 | -5.15 | -0.34 | -0.63 |
| Earnings per share, diluted | -2.93 | -5.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 47.1M | 61.6M | 9.73M | 15.6M |
| Short-term investments | 63.0M | 12.0M | 254.0K | 546.0K |
| Current assets | 111.9M | 74.1M | 10.4M | 16.5M |
| Total assets | 117.2M | 77.5M | 10.5M | 16.8M |
| Accounts payable | 2.07M | 2.30M | 1.03M | 259.0K |
| Current liabilities | 10.5M | 4.93M | 1.38M | 595.0K |
| Total debt | 441.0K | 779.0K | 162.0K | 262.0K |
| Total liabilities | 10.5M | 5.39M | 45.3M | 44.7M |
| Shareholders' equity | 106.6M | -54.6M | -34.8M | -27.9M |
| Shares outstanding | 21.8M | 4.07M | 21.4M | 21.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -54.2M | -18.1M | -5.82M | -10.5M |
| Capital spending | -95.0K | -109.0K | 0 | 0 |
| Free cash flow | -54.3M | -18.2M | -5.82M | -10.5M |
| Cash from investing | -49.7M | -12.0M | -1.00M | |
| Cash from financing | 89.2M | 82.0M | 0 | 225.0K |
| Share buybacks | 195.0K | |||
| Change in cash | -14.6M | 51.9M | -5.82M | -11.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2026 | Insider trade | SEC |
All 120 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 8, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 17, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Jul 10, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 10, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 12, 2026 | Management or board change | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 3, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 25, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 23, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| 8-K · Current report | Feb 27, 2026 | Current report | SEC |
| 8-K · Current report | Feb 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 5, 2025 | Current report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 28, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 13, 2025 | Offer document | SEC |
| 424B4 · Prospectus | Feb 13, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 13, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2025 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Feb 12, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 6, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 23, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Dec 20, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Dec 20, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 10, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Nov 27, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Nov 27, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Oct 24, 2024 | Offer document | SEC |
| D | May 15, 2024 | Other filings | SEC |
| D | Jun 7, 2021 | Other filings | SEC |
| D | May 24, 2019 | Other filings | SEC |
Cap table
Built by 6ix from Aardvark Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 21,891,271
- Fully diluted
- 21,891,271
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 21,891,271 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 21,891,271 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan E. Graf Other companies: CG Oncology, Inc. (Director · Since at least Jan 24, 2024); Epizyme Inc (Chief Business Officer · Apr 25, 2016 – Feb 9, 2018 · Past) | Board Member · Since at least Feb 12, 2025 |
| Jeffrey Chi Other companies: Scilex Holding Company (Director · Jan 6, 2021 – Jan 6, 2021 · Past) | Vice Chairman · Since at least Feb 12, 2025 |
| Victor Edward Tong Jr Other companies: CG Oncology, Inc. (Director · Since at least Jan 24, 2024) | Director · Since at least Feb 12, 2025 |
| Victor Tong Other companies: CG Oncology, Inc. (Managing Director, Decheng Capital · Since at least Nov 5, 2026) | Managing Director · Since at least Nov 5, 2026 |
| Bryan Jones | Chief Operating Officer · Since at least Feb 12, 2025 |
| Christopher J. Kemmerer | EVP, Technical Operations · Since at least Nov 4, 2026 |
| David Zhang | Chief Strategy Officer · Since at least Oct 8, 2026 |
| Derrick Li | Chief Business Officer · Since at least Feb 12, 2026 |
| Dvorit Samid | EVP, Medical Affairs · Since at least Nov 4, 2026 |
| Justin Stege | VP, Head of Project Management and Strategy · Since at least Nov 4, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Manasi Jaiman | Chief Medical Officer · Since at least Dec 10, 2025 |
| Nelson Sun | Chief Operating Officer & Chief Financial Officer · Since at least Feb 12, 2025 |
| Ron Lewis | VP, Head of CMC · Since at least Nov 4, 2026 |
| Roy Baynes | Director · Since at least Nov 4, 2026 |
| Tien Lee | Chief Executive Officer · Since at least Oct 23, 2026 |
| Zhenhuan Zheng | Chief Research Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Aardvark Therapeutics, Inc.